Harm reduction approaches for the use of benzodiazepines: A scoping review (2025)

BACKGROUND: Benzodiazepines are widely prescribed but are associated with significant risks, particularly when used long-term. The anxiolytic and hypnotic properties of these medications increase their risk of dependence, which can lead to nonmedical and illicit use. Illicit use further compounds these harms, particularly with the emergence of potent novel benzodiazepines on the unregulated market. While tapering remains the standard treatment, not all individuals seek discontinuation. In such cases, harm reduction becomes a key approach to minimise associated risks. This review aimed to identify and synthesise existing harm reduction approaches for people using benzodiazepines.
METHOD: A systematic search was conducted across four databases, PsycINFO (n = 183), MEDLINE (n = 345), Web of Science (n = 382), and Embase (n = 940), following the PRISMA guidelines. Searches were carried out between February 14 and March 30, 2024, using terms related to harm reduction and benzodiazepines. The search was re-run on July 7, 2025, using the same strategy across all four databases.
RESULTS: Thirty-five studies were included and grouped into the following themes: direct interventions (n = 16), policy approaches (n = 9), and population-specific approaches (n = 10). Among direct interventions, drug checking was the most frequently reported approach, with advanced techniques improving the detection of novel benzodiazepines and prompting safer use practices. Benzodiazepine agonist prescribing during the COVID-19 pandemic has yielded positive outcomes; conversely, policy responses such as rescheduling and prescribing changes indicated mixed results. While some studies reported reduced use and improved treatment engagement, others highlighted unintended consequences that may displace or exacerbate harm. Specific populations, such as young people, those who inject benzodiazepines, and members of online communities, highlight the diverse demographics of people who use benzodiazepines and emphasise the importance of developing tailored responses to address unique needs.
CONCLUSION: Drug checking emerged as the most widely reported harm reduction approach for benzodiazepine use, with consistent positive outcomes across studies. Prescribing and policy interventions demonstrated variable impacts, often influenced by broader systemic factors. Critically, a clear gap remains in harm reduction approaches for those not seeking treatment, highlighting a need for inclusive, flexible and pragmatic responses. There is also a need for more robust evaluation of harm reduction interventions to strengthen the evidence base and inform practice. [Author's abstract]